Abstract
A collection of clinical data was conducted to assess the performance and tolerability of Cerviron® ovules in the treatment and management of various types of vaginitis in clinical practice. A total of 111 women aged between 20 and 70 years were included, 71 of whom were treated with Cerviron® ovules as monotherapy and 40 who used Cerviron® ovules as supportive treatment in conjunction with antibiotic therapy. The aim of our study was to assess the relief in vaginal symptoms and changes in the normal vaginal pH level after 3 months of treatment with Cerviron® medical device in real-life clinical practice settings. The results showed that Cerviron® ovules are well tolerated and effective as monotherapy and also as an adjuvant to antibiotic therapy. The study and its details are registered in www.clinicaltrials.gov under ID NCT05652959.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05652959
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was waived by National Ethics Committee of Medicines And Medical Devices from Romania because this is a post-marketing study designed with the purpose of collecting additional data. According to the European Medical Device Regulation MDR 2017/745, concerning data collected in the post-marketing clinical follow-up plan for medical devices, Annex XIV, part B, the Notified Body shall ensure that the clinical evaluation adequately addresses the relevant safety and performance requirements that it is appropriately aligned with the risk management requirements. A Notified Body (ENTE CERTIFICATIONE MACCHINE SRL) reviewed the post-marketing clinical follow-up plan, including ethical considerations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.